HomeBUSINESS
BUSINESS

Sumitomo Dainippon Begins Japan PIII for Poxel’s Diabetes Med
(Dec.28.2017)

Sumitomo Dainippon Pharma and France’s Poxel have launched a PIII clinical trial program in Japan for imeglimin, an investigational type 2 diabetes drug developed by the Merck Serono spinoff, with its filing eyed for 2020, the two companies said on December 27 ...
(LOG IN FOR FULL STORY)